You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
MANAGEMENT TEAM
Hepeng Shi
Founder, Chairman and CEO of Avistone
Ph.D. from Peking Union Medical College.
Prior to founding Beijing Avistone Biotechnology Co., Ltd., Dr. Shi spearheaded the turnaround of Yangtze River Pharmaceutical Group's Beijing Haiyan Pharmaceutical Co., transforming it from a loss-making entity to a profitable one. He oversaw the successful launch and commercialization of Suhuang Zhike Capsules, which became a blockbuster product with annual domestic sales exceeding 2 billion RMB.Dr. Shi also led Beijing Pearl Biotechnology Co., Ltd.— now a wholly-owned subsidiary of Beijing Avistone Biotechnology Co., Ltd. — in earning the prestigious "G20 Innovation Leader" designation during Beijing's 13th Five-Year Plan period (2016–2020). His clinical research leadership includes directing Phase I/II/III trials for Vebreltinib, a first-in-class therapy targeting secondary glioblastoma with PTPRZ1-MET fusion gene-positive mutations. Currently, he oversees the commercialization of Avistone's marketed pharmaceuticals. Recognized as one of Beijing's Top 100 Leading Talents and a High-level Innovation and Entrepreneurship Talent, Dr. Shi has driven Avistone's cutting-edge research and development initiatives, achieving significant milestones.
-
Peilong Zhang
Chief Technology Officer (CTO), Avistone
Chief Technology Officer (CTO), Avistone
Peilong Zhang
Ph.D. in Organic Chemistry, Beijing Institute of Technology
As a founding member of Avistone, he is responsible for the development of innovative drugs. He has over 17 years of experience in innovative drug development, having led multiple new drug projects. He is the primary inventor of several clinical-stage drug candidates and directed numerous clinical studies. His expertise in small-molecule targeted drug design has led to significant breakthroughs, and he is recognized as an innovative team leader with extensive management experience.
-
Weizhe Xue
Senior Director of Clinical Operations, Avistone
Senior Director of Clinical Operations, Avistone
Weizhe Xue
Ph.D. in Applied Chemistry, Beijing Institute of Technology
As a founding member of Avistone, he is responsible for the clinical development of the company's innovative drugs. He has over 10 years of experience in innovative drug development and leads several clinical research projects including Vebreltinib's project. He has undertaken the Ministry of Science and Technology's "13th Five-Year Plan Major New Drug Creation and Development Program" and Beijing Municipal Government's "Clinical Research of Innovative Therapeutic Candidates and Key Technology Upgrades" special project. He has expertise in clinical protocol design and project management.
-
Gong Li
Senior Director of Medicinal Chemistry, Avistone
Senior Director of Medicinal Chemistry, Avistone
Gong Li
Ph.D. in Chemical Biology, Peking University
He is responsible for the design of small - molecule targeted drugs at the company. He previously worked at Beijing Hanmi Pharm. Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd. With over 10 years of experience in new drug R&D, he has successfully advanced multiple projects into clinical research and obtained 10 invention patents. He has expertise in the field of small - molecule targeted drug design.
-
Gang Li
Senior Director of Pharmacy, Avistone
Senior Director of Pharmacy, Avistone
Gang Li
Major in Pharmaceutics, Shenyang Pharmaceutical University
He has over 20 years of experience in innovative drugs development, quality research, new drug NDA submissions and industrialization, etc. He specializes in the process development and industrialization of poorly soluble drugs. He has led the entire pharmaceutical research of projects such as Vebreltinib project from early clinical stage to commercial manufacturing.
-
Di Han
Medical Director, Avistone
Medical Director, Avistone
Di Han
Graduated from Shenyang Pharmaceutical University
She has more than 10 years of experience in the research and development of biopharmaceuticals, and possesses rich experience and profound professional knowledge in medical research, clinical development, pharmacovigilance, and clinical quality. She has successfully facilitated the approval of multiple Investigational New Drug (IND) applications and New Drug Application (NDA) projects, including Vebreltinib.
-
Peipei Yang
VP of Clinical Operations (ex-China), Avistone
VP of Clinical Operations (ex-China), Avistone
Peipei Yang
Master of Science degree in Healthcare, Northumbria University, Newcastle, United Kingdom
Responsible for managing Avistone's overseas clinical operations team. Prior to Avistone, she worked at Novartis, IQVIA, and SystImmune (US subsidiary of Baili Pharmaceuticals). With over 14 years of global clinical operations/development experience, she specializes in building and leading international clinical operations teams to drive multi-regional clinical trials (MRCTs).
